Outcome Parameters After Allogeneic BMT for AML
| . | AML 1st CR (n = 31) . | AML 2nd CR (n = 8) . |
|---|---|---|
| Engraftment | ||
| Median transplant cell dose ×107/kg (range) | 2.68 (0.69-7.44) | 2.9 (1.08-4.60) |
| Median days to sustained* ANC ≥500 (range) | 13 (11-19)† | 14 (11-21)‡ |
| Median days to sustained1-153 platelet count ≥20,000 (range) | 24 [12-93] | 25 (15-43) |
| Posttransplant EBV-LPD | 3 | 0 |
| GVHD | ||
| Acute, grade I | 2 | 0 |
| Acute, grade II-IV | 0 | 0 |
| Chronic | 21-155 | 0 |
| Causes of death | ||
| Relapse | 1 | 1 |
| Infectious causes | 2 CMV pneumonitis¶ | 1 CMV pneumonitis |
| 1 fungal pneumonia | 1 toxoplasmosis | |
| 1 P carinii pneumonia | ||
| GVHD and secondary complications | 1 | |
| Secondary complications related to treatment of EBV-LPD | 1 | |
| Other | 1 late IP | |
| Alive and no evidence of disease | 24 | 4 |
| Sustained complete donor chimerism in bone marrow | 23 | 4 |
| Median f/u months (range) | 56.2 (28.4-66.2) | 47.5 (37.9-47.5) |
| . | AML 1st CR (n = 31) . | AML 2nd CR (n = 8) . |
|---|---|---|
| Engraftment | ||
| Median transplant cell dose ×107/kg (range) | 2.68 (0.69-7.44) | 2.9 (1.08-4.60) |
| Median days to sustained* ANC ≥500 (range) | 13 (11-19)† | 14 (11-21)‡ |
| Median days to sustained1-153 platelet count ≥20,000 (range) | 24 [12-93] | 25 (15-43) |
| Posttransplant EBV-LPD | 3 | 0 |
| GVHD | ||
| Acute, grade I | 2 | 0 |
| Acute, grade II-IV | 0 | 0 |
| Chronic | 21-155 | 0 |
| Causes of death | ||
| Relapse | 1 | 1 |
| Infectious causes | 2 CMV pneumonitis¶ | 1 CMV pneumonitis |
| 1 fungal pneumonia | 1 toxoplasmosis | |
| 1 P carinii pneumonia | ||
| GVHD and secondary complications | 1 | |
| Secondary complications related to treatment of EBV-LPD | 1 | |
| Other | 1 late IP | |
| Alive and no evidence of disease | 24 | 4 |
| Sustained complete donor chimerism in bone marrow | 23 | 4 |
| Median f/u months (range) | 56.2 (28.4-66.2) | 47.5 (37.9-47.5) |
*Sustained denotes 3 consecutive days.
Eleven of 31 patients received G-CSF (see text).
Five of 8 patients received G-CSF (see text).
Sustained denotes 3 consecutive days and platelet transfusion independent.
One of these two cases occurred solely as a complication of treatment of EBV-LPD with donor leukocytes (see text).
¶One of these two patients also had hepatic veno-occlusive disease.